---
document_datetime: 2025-12-02 05:30:57
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/inlyta.html
document_name: inlyta.html
version: success
processing_time: 0.1149199
conversion_datetime: 2025-12-28 13:56:18.10561
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Inlyta

[RSS](/en/individual-human-medicine.xml/66148)

##### Authorised

This medicine is authorised for use in the European Union

axitinib Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Inlyta](#more-information-on-inlyta-630)
- [More information on Inlyta](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Inlyta. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Inlyta.

Expand section

Collapse section

## What is Inlyta?

Inlyta is a medicine that contains the active substance axitinib. It is available as tablets (1, 3, 5 and 7 mg).

## What is Inlyta used for?

Inlyta is used to treat adults with advanced renal cell carcinoma, a type of kidney cancer. 'Advanced' means that the cancer has started to spread. Inlyta is used when treatment with Sutent (sunitinib) or 'cytokines' (other cancer medicines) has failed.

The medicine can only be obtained with a prescription.

## How is Inlyta used?

Treatment with Inlyta should be started by doctors who have experience in using cancer medicines.

The recommended starting dose is 5 mg twice a day, taken approximately 12 hours apart. The dose can be adjusted according to the patient's response. In patients who tolerate the 5 mg dose well, who do not have high blood pressure and are not taking blood pressure medicines, the dose may be increased first to 7 mg then to a maximum of 10 mg twice a day. It may be necessary to reduce the dose or interrupt treatment to manage certain side effects. In patients taking certain other medicines, the doctor may need to adjust the dose of Inlyta.

Patients with moderately reduced liver function should receive a starting dose of 2 mg twice a day. Inlyta should not be used in patients with severely reduced liver function.

## How does Inlyta work?

The active substance in Inlyta, axitinib, works by blocking some enzymes known as tyrosine kinases that are found in 'vascular endothelial growth factor' (VEGF) receptors on the surface of cancer cells. VEGF receptors are involved in the growth and spread of cancer cells and in the development of blood vessels that supply the tumours. By blocking these receptors, Inlyta helps to reduce the growth and spread of the cancer and cut off the blood supply that keeps the cancer cells growing.

## How has Inlyta been studied?

Inlyta has been compared with sorafenib (another cancer medicine) in one main study involving 723 patients with advanced renal cell carcinoma whose previous treatment with other cancer medicines such as sunitinib or cytokines had failed. The main measure of effectiveness was how long the patients lived without their tumour getting worse.

## What benefit has Inlyta shown during the studies?

Inlyta was more effective than sorafenib in treating advanced renal cell carcinoma. Patients taking Inlyta lived for an average of 6.7 months without the disease getting worse, compared with 4.7 months in the patients taking sorafenib. Effects were better for those patients who were previously treated with cytokines rather than sunitinib.

## What is the risk associated with Inlyta?

The most common side effects with Inlyta (seen in more than 20% of patients) are diarrhoea, hypertension (high blood pressure), fatigue (tiredness), dysphonia (speech disturbance), nausea (feeling sick), vomiting, decreased appetite, weight loss, palmar-plantar erythrodysaesthesia syndrome (rash and numbness on the palms of the hands and soles of the feet), haemorrhage (bleeding), hypothyroidism (an underactive thyroid gland), protein in urine, cough and constipation.

For the full list of all side effects and restrictions with Inlyta, see the package leaflet.

## Why has Inlyta been approved?

The CHMP concluded that the effectiveness of Inlyta in treating patients with advanced renal cell carcinoma for whom treatment with Sutent or a cytokine failed has been demonstrated. Regarding its safety, the side effects of the medicine are similar to other medicines in the same class and are considered to be acceptable and manageable. The CHMP therefore decided that Inlyta's benefits are greater than its risks and recommended that it be given marketing authorisation.

## What measures are being taken to ensure the safe and effective use of Inlyta?

A risk management plan has been developed to ensure that Inlyta is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Inlyta, including the appropriate precautions to be followed by healthcare professionals and patients.

## Other information about Inlyta

The European Commission granted a marketing authorisation valid throughout the European Union for Inlyta on 3 September 2012.

For more information about treatment with Inlyta, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Inlyta : EPAR - Summary for the public

Reference Number: EMA/349932/2012

English (EN) (75.52 KB - PDF)

**First published:** 13/09/2012

**Last updated:** 21/08/2015

[View](/en/documents/overview/inlyta-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-922)

български (BG) (103.15 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

21/08/2015

[View](/bg/documents/overview/inlyta-epar-summary-public_bg.pdf)

español (ES) (80.14 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

21/08/2015

[View](/es/documents/overview/inlyta-epar-summary-public_es.pdf)

čeština (CS) (100.41 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

21/08/2015

[View](/cs/documents/overview/inlyta-epar-summary-public_cs.pdf)

dansk (DA) (79.53 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

21/08/2015

[View](/da/documents/overview/inlyta-epar-summary-public_da.pdf)

Deutsch (DE) (81.47 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

21/08/2015

[View](/de/documents/overview/inlyta-epar-summary-public_de.pdf)

eesti keel (ET) (79.01 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

21/08/2015

[View](/et/documents/overview/inlyta-epar-summary-public_et.pdf)

ελληνικά (EL) (105.11 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

21/08/2015

[View](/el/documents/overview/inlyta-epar-summary-public_el.pdf)

français (FR) (80.11 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

21/08/2015

[View](/fr/documents/overview/inlyta-epar-summary-public_fr.pdf)

hrvatski (HR) (95.85 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

21/08/2015

[View](/hr/documents/overview/inlyta-epar-summary-public_hr.pdf)

italiano (IT) (79.49 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

21/08/2015

[View](/it/documents/overview/inlyta-epar-summary-public_it.pdf)

latviešu valoda (LV) (97.53 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

21/08/2015

[View](/lv/documents/overview/inlyta-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (98.24 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

21/08/2015

[View](/lt/documents/overview/inlyta-epar-summary-public_lt.pdf)

magyar (HU) (96.76 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

21/08/2015

[View](/hu/documents/overview/inlyta-epar-summary-public_hu.pdf)

Malti (MT) (101.31 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

21/08/2015

[View](/mt/documents/overview/inlyta-epar-summary-public_mt.pdf)

Nederlands (NL) (79.85 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

21/08/2015

[View](/nl/documents/overview/inlyta-epar-summary-public_nl.pdf)

polski (PL) (100.22 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

21/08/2015

[View](/pl/documents/overview/inlyta-epar-summary-public_pl.pdf)

português (PT) (80.31 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

21/08/2015

[View](/pt/documents/overview/inlyta-epar-summary-public_pt.pdf)

română (RO) (96.7 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

21/08/2015

[View](/ro/documents/overview/inlyta-epar-summary-public_ro.pdf)

slovenčina (SK) (99.97 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

21/08/2015

[View](/sk/documents/overview/inlyta-epar-summary-public_sk.pdf)

slovenščina (SL) (94.27 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

21/08/2015

[View](/sl/documents/overview/inlyta-epar-summary-public_sl.pdf)

Suomi (FI) (79.18 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

21/08/2015

[View](/fi/documents/overview/inlyta-epar-summary-public_fi.pdf)

svenska (SV) (79.53 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

21/08/2015

[View](/sv/documents/overview/inlyta-epar-summary-public_sv.pdf)

Inlyta : EPAR - Risk-management-plan

English (EN) (2.71 MB - PDF)

**First published:** 26/06/2019

**Last updated:** 16/08/2024

[View](/en/documents/rmp-summary/inlyta-epar-risk-management-plan_en.pdf)

## Product information

Inlyta : EPAR - Product Information

English (EN) (485.44 KB - PDF)

**First published:** 13/09/2012

**Last updated:** 22/01/2025

[View](/en/documents/product-information/inlyta-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-674)

български (BG) (469.27 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/01/2025

[View](/bg/documents/product-information/inlyta-epar-product-information_bg.pdf)

español (ES) (921.25 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/01/2025

[View](/es/documents/product-information/inlyta-epar-product-information_es.pdf)

čeština (CS) (406.67 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/01/2025

[View](/cs/documents/product-information/inlyta-epar-product-information_cs.pdf)

dansk (DA) (859.76 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/01/2025

[View](/da/documents/product-information/inlyta-epar-product-information_da.pdf)

Deutsch (DE) (645.03 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/01/2025

[View](/de/documents/product-information/inlyta-epar-product-information_de.pdf)

eesti keel (ET) (551.88 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/01/2025

[View](/et/documents/product-information/inlyta-epar-product-information_et.pdf)

ελληνικά (EL) (946.87 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/01/2025

[View](/el/documents/product-information/inlyta-epar-product-information_el.pdf)

français (FR) (519.31 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/01/2025

[View](/fr/documents/product-information/inlyta-epar-product-information_fr.pdf)

hrvatski (HR) (422.55 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/01/2025

[View](/hr/documents/product-information/inlyta-epar-product-information_hr.pdf)

íslenska (IS) (421.69 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/01/2025

[View](/is/documents/product-information/inlyta-epar-product-information_is.pdf)

italiano (IT) (422.11 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/01/2025

[View](/it/documents/product-information/inlyta-epar-product-information_it.pdf)

latviešu valoda (LV) (516.68 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/01/2025

[View](/lv/documents/product-information/inlyta-epar-product-information_lv.pdf)

lietuvių kalba (LT) (444.47 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/01/2025

[View](/lt/documents/product-information/inlyta-epar-product-information_lt.pdf)

magyar (HU) (882.96 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/01/2025

[View](/hu/documents/product-information/inlyta-epar-product-information_hu.pdf)

Malti (MT) (854.31 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/01/2025

[View](/mt/documents/product-information/inlyta-epar-product-information_mt.pdf)

Nederlands (NL) (415.11 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/01/2025

[View](/nl/documents/product-information/inlyta-epar-product-information_nl.pdf)

norsk (NO) (358.3 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/01/2025

[View](/no/documents/product-information/inlyta-epar-product-information_no.pdf)

polski (PL) (416.89 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/01/2025

[View](/pl/documents/product-information/inlyta-epar-product-information_pl.pdf)

português (PT) (424.78 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/01/2025

[View](/pt/documents/product-information/inlyta-epar-product-information_pt.pdf)

română (RO) (421.62 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/01/2025

[View](/ro/documents/product-information/inlyta-epar-product-information_ro.pdf)

slovenčina (SK) (413.42 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/01/2025

[View](/sk/documents/product-information/inlyta-epar-product-information_sk.pdf)

slovenščina (SL) (358.18 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/01/2025

[View](/sl/documents/product-information/inlyta-epar-product-information_sl.pdf)

Suomi (FI) (388.62 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/01/2025

[View](/fi/documents/product-information/inlyta-epar-product-information_fi.pdf)

svenska (SV) (842.99 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

22/01/2025

[View](/sv/documents/product-information/inlyta-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000245212 21/01/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Inlyta : EPAR - All Authorised presentations

English (EN) (28.77 KB - PDF)

**First published:** 13/09/2012

**Last updated:** 05/09/2013

[View](/en/documents/all-authorised-presentations/inlyta-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-956)

български (BG) (52.24 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

05/09/2013

[View](/bg/documents/all-authorised-presentations/inlyta-epar-all-authorised-presentations_bg.pdf)

español (ES) (29.1 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

05/09/2013

[View](/es/documents/all-authorised-presentations/inlyta-epar-all-authorised-presentations_es.pdf)

čeština (CS) (43.24 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

05/09/2013

[View](/cs/documents/all-authorised-presentations/inlyta-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (24.37 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

05/09/2013

[View](/da/documents/all-authorised-presentations/inlyta-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (24.82 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

05/09/2013

[View](/de/documents/all-authorised-presentations/inlyta-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (29.48 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

05/09/2013

[View](/et/documents/all-authorised-presentations/inlyta-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (44.63 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

05/09/2013

[View](/el/documents/all-authorised-presentations/inlyta-epar-all-authorised-presentations_el.pdf)

français (FR) (25.16 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

05/09/2013

[View](/fr/documents/all-authorised-presentations/inlyta-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (36.22 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

05/09/2013

[View](/hr/documents/all-authorised-presentations/inlyta-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (24.14 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

05/09/2013

[View](/is/documents/all-authorised-presentations/inlyta-epar-all-authorised-presentations_is.pdf)

italiano (IT) (20.79 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

05/09/2013

[View](/it/documents/all-authorised-presentations/inlyta-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (38.99 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

05/09/2013

[View](/lv/documents/all-authorised-presentations/inlyta-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (38.42 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

05/09/2013

[View](/lt/documents/all-authorised-presentations/inlyta-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (38.15 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

05/09/2013

[View](/hu/documents/all-authorised-presentations/inlyta-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (35.7 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

05/09/2013

[View](/mt/documents/all-authorised-presentations/inlyta-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (18.26 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

05/09/2013

[View](/nl/documents/all-authorised-presentations/inlyta-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (18.62 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

05/09/2013

[View](/no/documents/all-authorised-presentations/inlyta-epar-all-authorised-presentations_no.pdf)

polski (PL) (28.09 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

05/09/2013

[View](/pl/documents/all-authorised-presentations/inlyta-epar-all-authorised-presentations_pl.pdf)

português (PT) (21.32 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

05/09/2013

[View](/pt/documents/all-authorised-presentations/inlyta-epar-all-authorised-presentations_pt.pdf)

română (RO) (34.14 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

05/09/2013

[View](/ro/documents/all-authorised-presentations/inlyta-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (34.74 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

05/09/2013

[View](/sk/documents/all-authorised-presentations/inlyta-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (26.25 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

05/09/2013

[View](/sl/documents/all-authorised-presentations/inlyta-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (27.27 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

05/09/2013

[View](/fi/documents/all-authorised-presentations/inlyta-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (19.35 KB - PDF)

**First published:**

13/09/2012

**Last updated:**

05/09/2013

[View](/sv/documents/all-authorised-presentations/inlyta-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Inlyta Active substance axitinib International non-proprietary name (INN) or common name axitinib Therapeutic area (MeSH) Carcinoma, Renal Cell Anatomical therapeutic chemical (ATC) code L01EK01

### Pharmacotherapeutic group

Protein kinase inhibitors

### Therapeutic indication

Inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.

## Authorisation details

EMA product number EMEA/H/C/002406 Marketing authorisation holder

Pfizer Europe MA EEIG

Boulevard de la Plaine 17

Opinion adopted 24/05/2012 Marketing authorisation issued 03/09/2012 Revision 17

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Inlyta : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (179.24 KB - PDF)

**First published:** 14/04/2025

[View](/en/documents/procedural-steps-after/inlyta-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Inlyta : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (205.6 KB - PDF)

**First published:** 18/07/2013

**Last updated:** 15/04/2025

[View](/en/documents/procedural-steps-after/inlyta-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Inlyta-H-C-PSUSA-00010022-201901 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/564202/2019

English (EN) (65.23 KB - PDF)

**First published:** 22/11/2019

[View](/en/documents/scientific-conclusion/inlyta-h-c-psusa-00010022-201901-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Inlyta : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/453325/2012

English (EN) (1.18 MB - PDF)

**First published:** 13/09/2012

**Last updated:** 13/09/2012

[View](/en/documents/assessment-report/inlyta-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Inlyta

Adopted

Reference Number: EMA/293828/2012

English (EN) (45.55 KB - PDF)

**First published:** 25/05/2012

**Last updated:** 25/05/2012

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-inlyta_en.pdf)

#### More information on Inlyta

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu310844) on 23 February 2011. Inlyta was withdrawn from the Community register of orphan medicinal products in July 2012 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.

#### More information on Inlyta

- [Real-world treatment patterns and outcomes of patients with advanced renal cell carcinoma (aRCC) treated with first-line (1L) axitinib + pembrolizumab therapy - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000104)
- [Non-interventional post-marketing safety study (PMSS) to collect information on hepatic function disorders among Japanese patients with radically unresectable or metastatic renal cell carcinoma treated with pembrolizumab in combination with axitinib (MK-3475-A97) - post-authorisation study](https://catalogues.ema.europa.eu/study/48486)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 22/01/2025

## Share this page

[Back to top](#main-content)